Jerzy Jedrychowski, MD
Internal Medicine · New Britain, CTNPI 1790722049
Payments from drug & device makers
Across 356 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$950
- Lilly USA, LLC$658
- Amgen$597
- Boehringer Ingelheim$509
- Pfizer$463
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,707100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 81 | $1,919 |
| AbbVie(2 entities) | 61 | $950 |
| Lilly USA, LLC | 29 | $658 |
| Amgen(2 entities) | 38 | $597 |
| Boehringer Ingelheim | 11 | $509 |
| Pfizer | 28 | $463 |
| Abbott | 6 | $421 |
| Novo Nordisk | 12 | $364 |
| Esperion Therapeutics, Inc. | 9 | $262 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $206 |
| Johnson & Johnson | 11 | $159 |
| Bayer | 2 | $150 |
| Novartis | 7 | $147 |
| Merck | 8 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Amarin Pharma, Inc. | 4 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| Alkermes, Inc. | 3 | $69 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| Eisai Inc. | 3 | $50 |
| Bausch Health US, LLC | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Exact Sciences | 1 | $31 |
| GSK | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$704
- JARDIANCE$361
- Ozempic$126
- FREESTYLE LIBRE 3$125
- UBRELVY$125
- Kerendia$123
- FreeStyle Libre$118
- FreeStyle Libre 2$115
- NEXLIZET$115
- NEXLETOL$115
- Repatha$110
How this compares
$7,726 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $266,313 |
| FarxigaDapagliflozin Propanediol | 82 | $113,113 |
| MounjaroTirzepatide | 55 | $97,709 |
| EliquisApixaban | 63 | $92,790 |
| XareltoRivaroxaban | 55 | $82,405 |
| JanuviaSitagliptin Phosphate | 48 | $78,394 |
| JardianceEmpagliflozin | 38 | $64,698 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $27,117 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $23,836 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $23,009 |
| Repatha SureclickEvolocumab | 26 | $22,718 |
| MyrbetriqMirabegron | 20 | $14,006 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $10,472 |
| Atorvastatin Calcium | 606 | $4,104 |
| Nebivolol Hcl | 69 | $3,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $364 | $266,313147 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,919 | $136,122111 claims |
| MerckJanuvia, Janumet Xr | $134 | $105,51264 claims |
| Lilly USA, LLCMounjaro | $658 | $97,70955 claims |
| PfizerEliquis | $463 | $92,79063 claims |
| Johnson & JohnsonXarelto | $159 | $82,40555 claims |
| Boehringer IngelheimJardiance | $509 | $64,69838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in New Britain
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.